Enzymlogic will be presenting its optimized kinetic profiling assays to identify reversible (KINETICfinder®) and irreversible compounds (COVALfinder®) at this 2-day event in Cambridge.
The meeting will focus on the use of binding kinetics and mechanistic PK/PD modeling in informing early drug discovery decisions. Further, the deliberations will strive to delve deeper into the importance of aspects like association, dissociation, rebinding and residence time of target-small molecule interactions.
Additionally, it will shed critical light on the role of binding kinetics, target vulnerability, protein turnover and uptake/efflux of the small-molecule in modelling target occupancy metrics and, thus eventually, dosing decisions.